Summary of polymorphic immune response genes reported in the literature to be associated with increased (risk) or decreased (protective) frequency of inhibitors in the literature
| Gene . | Type of polymorphism . | Effect . | Reference . |
|---|---|---|---|
| Interleukin 10 (IL 10) | Microsatellite | Risk | 40 |
| SNP | Risk | 41 | |
| SNP | Risk | 42 | |
| SNP Haplotype | Risk | 43 | |
| SNP Haplotype | Risk | 44 | |
| SNP Haplotype | Risk | 45 | |
| SNP Haplotype | Risk | 46 | |
| Interleukin 1α (IL-1α) | SNP Haplotype | Risk | 43 |
| Interleukin 1β (IL-1β) | SNP Haplotype | Protective | 43 |
| Interleukin 2 (IL-2) | SNP Haplotype | Protective | 43 |
| Interleukin 5 (IL-5) | SNP | Risk | 47 |
| Interleukin 12A (IL-12A) | SNP Haplotype | Risk | 43 |
| Transforming Growth Factor β | NA | Protective | 48 |
| Tumor Necrosis Factor α (TNFA) | SNP | Risk | 45 |
| SNP | Risk | 41 | |
| SNP | Risk | 49 | |
| Cytotoxic T-lymphocyte Antigen 4 (CTLA4) | SNP | Risk | 50 |
| SNP | Protective | 51 | |
| CD40/CD40L | NA | Protective | 48 |
| CD44 | SNPs (2) | Risk | 33 |
| Protein Tyrosine Phosphatase, Receptor Type, M (PTPRM) | SNP | Risk | 33 |
| Tumor Necrosis Factor Receptor Superfamily, Member 21 (TNFRSF21) | SNP | Risk | 33 |
| Mitogen-activated Protein Kinase 9 (MAPK9) | SNP | Risk | 33 |
| Immunoglobulin Superfamily, Member 2 (IGSF2) | SNP | Protective | 33 |
| Macrophage Scavenger Receptor 1 (MSR1) | SNP | Protective | 33 |
| Protein Tyrosine Phosphatase, Receptor Type, E (PTPRE) | SNP | Protective | 33 |
| Heme Oxygenase-1-Encoding (HMOX1) | Microsatellite | Risk | 23 |
| Fc γ Receptors 2A (FCGR2A) | SNP | Risk | 52 |
| Gene . | Type of polymorphism . | Effect . | Reference . |
|---|---|---|---|
| Interleukin 10 (IL 10) | Microsatellite | Risk | 40 |
| SNP | Risk | 41 | |
| SNP | Risk | 42 | |
| SNP Haplotype | Risk | 43 | |
| SNP Haplotype | Risk | 44 | |
| SNP Haplotype | Risk | 45 | |
| SNP Haplotype | Risk | 46 | |
| Interleukin 1α (IL-1α) | SNP Haplotype | Risk | 43 |
| Interleukin 1β (IL-1β) | SNP Haplotype | Protective | 43 |
| Interleukin 2 (IL-2) | SNP Haplotype | Protective | 43 |
| Interleukin 5 (IL-5) | SNP | Risk | 47 |
| Interleukin 12A (IL-12A) | SNP Haplotype | Risk | 43 |
| Transforming Growth Factor β | NA | Protective | 48 |
| Tumor Necrosis Factor α (TNFA) | SNP | Risk | 45 |
| SNP | Risk | 41 | |
| SNP | Risk | 49 | |
| Cytotoxic T-lymphocyte Antigen 4 (CTLA4) | SNP | Risk | 50 |
| SNP | Protective | 51 | |
| CD40/CD40L | NA | Protective | 48 |
| CD44 | SNPs (2) | Risk | 33 |
| Protein Tyrosine Phosphatase, Receptor Type, M (PTPRM) | SNP | Risk | 33 |
| Tumor Necrosis Factor Receptor Superfamily, Member 21 (TNFRSF21) | SNP | Risk | 33 |
| Mitogen-activated Protein Kinase 9 (MAPK9) | SNP | Risk | 33 |
| Immunoglobulin Superfamily, Member 2 (IGSF2) | SNP | Protective | 33 |
| Macrophage Scavenger Receptor 1 (MSR1) | SNP | Protective | 33 |
| Protein Tyrosine Phosphatase, Receptor Type, E (PTPRE) | SNP | Protective | 33 |
| Heme Oxygenase-1-Encoding (HMOX1) | Microsatellite | Risk | 23 |
| Fc γ Receptors 2A (FCGR2A) | SNP | Risk | 52 |
For the HIGS combined cohort study, only SNPs associated with inhibitors in the subgroup of discordant brother pairs are shown.33